AstraZeneca wins $76M in Prilosec generic case

Canada's Apotex must pay AstraZeneca (AZN -0.1%) $76M in damages tied to the generic drug maker's sale of generic Prilosec.

The award amounts to 50% of the profits Apotex earned selling the drug over three-and-a-half years.

The patent infringement portion of the case was already decided (in 2007) and thus only the judgement amount is new.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs